PALISADE BIO, INC.: 10-Q filed 2019-05-14
What PALISADE BIO, INC. reported in its quarterly report filed 2019-05-14 (fiscal Q1 2019): 29 published measures, 61 facts as tagged in accession 0001171843-19-003354.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-05-14
- Fiscal period
- fiscal Q1 2019
- Accession
- 0001171843-19-003354 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PALISADE BIO, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 5,405,703 | USD | |
| At 2018-12-31 | 7,684,450 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 2,133,922 | USD | |
| At 2018-12-31 | 1,634,900 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 3,271,781 | USD | |
| At 2018-12-31 | 6,049,550 | USD | |
| At 2018-03-31 | 6,607,111 | USD | |
| At 2017-12-31 | 8,515,129 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 4,005,089 | USD | |
| At 2018-12-31 | 5,787,110 | USD | |
| At 2018-03-31 | 9,724,248 | USD | |
| At 2017-12-31 | 6,674,940 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -3,113,992 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -2,146,968 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -1,665,905 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -1,846,949 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -117,019 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -104,244 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 5,000,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | -216,737,885 | USD | |
| At 2018-12-31 | -213,623,893 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 75,668 | USD | |
| At 2018-12-31 | 90,311 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 337,966 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 238,835 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -2,456,565 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -2,348,995 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 4,538,277 | USD | |
| At 2018-12-31 | 6,508,393 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 2,017 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 1,920 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 1,210,073 | USD | |
| At 2018-12-31 | 1,051,166 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 237,782 | USD | |
| At 2018-12-31 | 294,057 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 2,459,065 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 2,351,495 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 1,514,463 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 1,169,441 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 18,205,060 | shares | |
| At 2018-12-31 | 18,205,060 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 219,819,771 | USD | |
| At 2018-12-31 | 219,481,805 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | -2,156 | USD | |
| At 2018-12-31 | -413 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 738,404 | USD | |
| At 2018-12-31 | 763,543 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-03-31 | 53,354 | USD | |
| At 2018-12-31 | 23,965 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -3,115,735 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -2,146,853 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 944,602 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 1,182,054 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -344,295 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -4,021 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -657,427 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 202,027 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | 2,017 | USD | 90 |
| 2018-01-01 to 2018-03-31 | 1,920 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-03-31 | -56,275 | USD | 90 |
| 2018-01-01 to 2018-03-31 | -175,430 | USD | 90 |
Inspect the source
- Entity
- PALISADE BIO, INC. / CIK 0001357459
- Captured
- 2026-09-20T07:55:46.162Z
- SEC response SHA-256
1d4973c07aed8ad894103731546b55683b331acdd472b37e4b33a98a2f63a74c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001357459.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))